Trial · NCT01350388
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
NCT01350388, Not applicable, Completed, University of Utah; results first posted 2016-10-03
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease. Trials, record NCT01350388. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01350388
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
- NCT number
- NCT01350388
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 80 participants, actual
- Lead sponsor
- University of Utah
- Conditions
- Chronic Kidney Disease, Diabetes
- Interventions
- Febuxostat, Placebo
- First posted
- 2011-05-09
- Last updated
- 2016-10-03
- Results first posted
- 2016-10-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks | Baseline and 24 weeks | The percent difference in thiobarbituric acid reactive substance (TBARS) concentration geometric mean values from baseline to 24 weeks was calculated for each arm |
| Primary | Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks | Baseline and 24 weeks | The percent difference in adiponectin concentration geometric mean values from baseline to 24 weeks was calculated for each arm |
| Primary | Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks | Baseline and 24 weeks | The percent difference in TGF-beta1 concentration geometric mean values from baseline to 24 weeks was calculated for each arm |
| Secondary | Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks | Baseline and 24 weeks | The percent difference in plasma TNF-α concentration geometric mean values from baseline to 24 weeks was calculated for each arm |
| Secondary | Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks | Baseline and 24 weeks | The percent difference in plasma IL-6 concentration geometric mean values from baseline to 24 weeks was calculated for each arm |
| Secondary | Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks | Baseline and 24 weeks | The percent difference in plasma hsCRP concentration geometric mean values from baseline to 24 weeks was calculated for each arm |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks | Baseline and 24 weeks | percent difference in geometric mean | GEOMETRIC_MEAN | |
| PRIMARY | Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks | Baseline and 24 weeks | percent difference in geometric mean | GEOMETRIC_MEAN | |
| PRIMARY | Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks | Baseline and 24 weeks | percent difference in geometric mean | GEOMETRIC_MEAN | |
| SECONDARY | Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks | Baseline and 24 weeks | percent difference in geometric mean | GEOMETRIC_MEAN | |
| SECONDARY | Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks | Baseline and 24 weeks | percent difference in geometric mean | GEOMETRIC_MEAN | |
| SECONDARY | Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks | Baseline and 24 weeks | percent difference in geometric mean | GEOMETRIC_MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks | Febuxostat | 34.0 | 95% Confidence Interval -26.3 to 143.4 | percent difference in geometric mean | |
| Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks | Placebo | 44.6 | 95% Confidence Interval -19.3 to 159.2 | percent difference in geometric mean | |
| Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks | Febuxostat | 2.3 | 95% Confidence Interval -23.4 to 36.7 | percent difference in geometric mean | |
| Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks | Placebo | -4.1 | 95% Confidence Interval -27.7 to 27.4 | percent difference in geometric mean | |
| Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks | Febuxostat | 29.8 | 95% Confidence Interval 4.4 to 61.5 | percent difference in geometric mean | |
| Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks | Placebo | 10.0 | 95% Confidence Interval -10.8 to 35.6 | percent difference in geometric mean | |
| Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks | Febuxostat | -9.9 | 95% Confidence Interval -30.6 to 16.8 | percent difference in geometric mean | |
| Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks | Placebo | -7.4 | 95% Confidence Interval -28.3 to 19.7 | percent difference in geometric mean | |
| Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks | Febuxostat | -24.0 | 95% Confidence Interval -35.3 to -10.7 | percent difference in geometric mean | |
| Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks | Placebo | -9.5 | 95% Confidence Interval -22.7 to 6.1 | percent difference in geometric mean |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Febuxostat | 40 | |
| Overall Study | STARTED | Placebo | 40 | |
| Overall Study | COMPLETED | Febuxostat | 37 | |
| Overall Study | COMPLETED | Placebo | 39 | |
| Overall Study | NOT COMPLETED | Febuxostat | 3 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Cholecystitis | Hepatobiliary disorders | Febuxostat | 0 | 40 | 0 |
| serious | Cholecystitis | Hepatobiliary disorders | Placebo | 1 | 40 | 1 |
| serious | Ischemic Stroke | Nervous system disorders | Febuxostat | 0 | 40 | 0 |
| serious | Ischemic Stroke | Nervous system disorders | Placebo | 1 | 40 | 1 |
| serious | Flu-like Symptoms | General disorders | Febuxostat | 0 | 40 | 0 |
| serious | Flu-like Symptoms | General disorders | Placebo | 1 | 40 | 1 |
| serious | Atrial Fibrillation | Cardiac disorders | Febuxostat | 0 | 40 | 0 |
| serious | Atrial Fibrillation | Cardiac disorders | Placebo | 1 | 40 | 1 |
| serious | Aortic Valve Disease | Cardiac disorders | Febuxostat | 1 | 40 | 1 |
| serious | Aortic Valve Disease | Cardiac disorders | Placebo | 0 | 40 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Febuxostat | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Febuxostat | 0 | 40 |
| Total, other adverse events | Placebo | 0 | 40 |
| Total, serious adverse events | Febuxostat | 1 | 40 |
| Total, serious adverse events | Placebo | 3 | 40 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28270924 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Febuxostat vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01350388
GET https://conductscience.org/api/trials/v1/NCT01350388/registered